TGFB1 and neoplasm: Taken together, our results suggest that combined GARP:TGF-β1/PD-1 blockade can exert anti-tumor activity via multiple mechanisms, not only by increasing effector functions of anti-tumor T cells already present within tumors, but also by increasing tumor blood vessel density and infiltration by new anti-tumor T cells.